Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biosimilar symbols : TEVJF save search
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Published: 2024-04-19 (Crawled : 10:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 1.16%
H: 7.28%
C: 1.3%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: 0.0%
humira biosimilar approved for agreement
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Published: 2024-04-16 (Crawled : 21:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
stelara fda biosimilar approval teva
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Published: 2024-04-04 (Crawled : 00:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
candidate biosimilar global for teva agreement
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Published: 2024-02-24 (Crawled : 04:20) - globenewswire.com
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
| Email alert
Add to watchlist
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
simlandi first biosimilar approval teva
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
Published: 2024-02-15 (Crawled : 12:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 0.32%
H: 2.98%
C: 0.32%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 1.66%
H: 1.96%
C: 0.49%
avt04 stelara biosimilar expected global market
Global Biosimilar Monoclonal Antibodies Market Report 2024: Future Market Growth Powered by Biologics and Personalized Therapy Advances
Published: 2024-02-14 (Crawled : 20:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.26%
H: 0.87%
C: 0.32%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.48%
H: 1.56%
C: 1.48%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.75%
H: 0.86%
C: 0.41%
biosimilar report global therapy growth market
Biosimilar Hormones Global Market Report 2024 - Niche Sectors Record Notable Market Contributions
Published: 2024-02-14 (Crawled : 03:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.16%
H: 0.43%
C: -2.76%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.21%
H: 0.34%
C: 0.07%
biosimilar report global market
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Published: 2024-01-29 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 2.39%
H: 4.67%
C: 1.67%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -1.05%
H: 0.41%
C: -0.35%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.11%
H: 0.7%
C: 0.65%
avt03 prolia biosimilar positive results study
STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara
Published: 2024-01-10 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -0.72%
H: 1.77%
C: -1.53%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.66%
H: 0.71%
C: 0.17%
first biosimilar approval stelara
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
Published: 2024-01-03 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 1.23%
H: 2.17%
C: 1.57%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.97%
H: 1.53%
C: 0.0%
avt06 eylea candidate biosimilar results study
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Published: 2023-11-29 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 1.02%
H: 0.0%
C: -5.05%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.04%
avt05 simponi biosimilar positive results study
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 0.33%
H: 3.87%
C: -0.55%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: 0.0%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.21%
H: 1.67%
C: 1.25%
avt04 stelara pharma biosimilar authorization
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
Published: 2023-11-10 (Crawled : 14:30) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 0.12%
H: 7.18%
C: 3.56%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.22%
H: 0.86%
C: 0.86%
biosimilar chmp positive stelara
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Published: 2023-10-03 (Crawled : 13:00) - biospace.com/
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 2.22%
H: 0.87%
C: -0.65%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.6%
H: 0.36%
C: -0.46%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.1%
H: 0.74%
C: -1.67%
xolair biosimilar commercialization agreement
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Published: 2023-10-03 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 2.22%
H: 0.87%
C: -0.65%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.6%
H: 0.36%
C: -0.46%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.1%
H: 0.74%
C: -1.67%
xolair biosimilar commercialization agreement
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
Published: 2023-09-25 (Crawled : 08:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 1.24%
H: 4.25%
C: -0.67%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 1.16%
H: 1.98%
C: -0.38%
avt04 stelara biosimilar japan approval
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
Published: 2023-09-20 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 2.12%
H: 0.0%
C: -2.5%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -0.95%
H: 1.92%
C: 1.15%
avt02 humira candidate biosimilar update
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
Published: 2023-06-12 (Crawled : 07:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -0.98%
H: 1.96%
C: -8.62%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.01%
H: 0.16%
C: -0.06%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -1.5%
H: 1.71%
C: 0.57%
avt04 stelara biosimilar license teva
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
Published: 2023-05-10 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 0.11%
H: 4.69%
C: 3.77%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: -1.04%
H: 1.89%
C: -0.42%
eylea biosimilar commercialization agreement
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Published: 2023-05-04 (Crawled : 09:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: -0.61%
H: 1.54%
C: -1.03%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.12%
H: 0.14%
C: -0.34%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 3.18%
H: 1.64%
C: 0.41%
avt05 simponi biosimilar study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.